Literature DB >> 10946360

Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred.

J E McDonald1, F J Miller, S E Hallam, L Nelson, D A Marchuk, K J Ward.   

Abstract

HHT type 2 (HHT 2) is a multi-system vascular dysplasia caused by a mutation in the ALK-1 gene, but the phenotype has not been well defined. We report on 51 members of an HHT 2 kindred with an ALK-1 gene mutation shown to be associated with the disorder. This ALK-1 mutation was detected in 38 kindred members who were evaluated systematically for associated vascular abnormalities. Pulmonary arteriovenous malformations (AVMs) were found in 6% of those screened, cerebral AVM in 7%, hepatic AVM in 17%, and spinal AVM in 3%. We discuss these and other findings in the 38 affected kindred members, as well as findings in the 13 kindred members in whom the mutation was not detected. This study shows that pulmonary, cerebral, spinal, and hepatic AVMs can all occur in HHT 2. It also adds to the evidence suggesting that pulmonary AVMs are more common in HHT 1 than in HHT 2. We identify a higher prevalence of hepatic AVMs than previously reported in either HHT 1 or 2. This may be specific to the mutation in this kindred, but probably reflects the lack of routine screening for this manifestation. Even in this family in which all affected individuals have the same mutation, the clinical manifestations of HHT and their severity varied tremendously. Intrafamilial variation in expression of HHT is clearly significant, emphasizing the difficulty in establishing the diagnosis in individuals and in sub-typing families when DNA testing is not available.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946360     DOI: 10.1002/1096-8628(20000814)93:4<320::aid-ajmg12>3.0.co;2-r

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  23 in total

Review 1.  Fishing for novel angiogenic therapies.

Authors:  Kameha R Kidd; Brant M Weinstein
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

2.  Elevated endothelial Sox2 causes lumen disruption and cerebral arteriovenous malformations.

Authors:  Jiayi Yao; Xiuju Wu; Daoqin Zhang; Lumin Wang; Li Zhang; Eric X Reynolds; Carlos Hernandez; Kristina I Boström; Yucheng Yao
Journal:  J Clin Invest       Date:  2019-06-24       Impact factor: 14.808

3.  [64-year old patient with tachycardia and signs of heart failure].

Authors:  M M Zaruba; T Waggershauser; S Weckbach; A Gerbes; O Mühling; S Kääb
Journal:  Internist (Berl)       Date:  2009-04       Impact factor: 0.743

Review 4.  The pathobiology of vascular malformations: insights from human and model organism genetics.

Authors:  Sarah E Wetzel-Strong; Matthew R Detter; Douglas A Marchuk
Journal:  J Pathol       Date:  2016-12-04       Impact factor: 7.996

5.  Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension.

Authors:  Ivana Nikolic; Lai-Ming Yung; Peiran Yang; Rajeev Malhotra; Samuel D Paskin-Flerlage; Teresa Dinter; Geoffrey A Bocobo; Kathleen E Tumelty; Anthony J Faugno; Luca Troncone; Megan E McNeil; Xiuli Huang; Kathryn R Coser; Carol S C Lai; Paul D Upton; Marie Jose Goumans; Roham T Zamanian; C Gregory Elliott; Arthur Lee; Wei Zheng; Stephen P Berasi; Christine Huard; Nicholas W Morrell; Raymond T Chung; Richard W Channick; Kari E Roberts; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2019-04-01       Impact factor: 21.405

6.  Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years.

Authors:  T Krings; A Ozanne; S M Chng; H Alvarez; G Rodesch; P L Lasjaunias
Journal:  Neuroradiology       Date:  2005-09-01       Impact factor: 2.804

7.  [Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia].

Authors:  C Rohrmeier; T S Kühnel
Journal:  HNO       Date:  2012-11       Impact factor: 1.284

8.  Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.

Authors:  R E Harrison; J A Flanagan; M Sankelo; S A Abdalla; J Rowell; R D Machado; C G Elliott; I M Robbins; H Olschewski; V McLaughlin; E Gruenig; F Kermeen; M Halme; A Räisänen-Sokolowski; T Laitinen; N W Morrell; R C Trembath
Journal:  J Med Genet       Date:  2003-12       Impact factor: 6.318

9.  Visceral manifestations in hereditary haemorrhagic telangiectasia type 2.

Authors:  S A Abdalla; U W Geisthoff; D Bonneau; H Plauchu; J McDonald; S Kennedy; M E Faughnan; M Letarte
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

10.  How to identify pediatric cerebral and pulmonary arteriovenous malformation earlier: non-hereditary hemorrhagic telangiectasia case.

Authors:  Yuhai Zhang; Weijie Chen; Meihua Qin; Chao Zhao; Zhen Xu; Jun Dong; Guoqing Sun; Yunxue Yang
Journal:  Childs Nerv Syst       Date:  2014-08-30       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.